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Summary 
GMP-140 is a 140-kD granule membrane protein, found in the c~ granules of platelets and the 
Weibd-Palade bodies of endothelial cells, that is surface expressed on cell activation and mediates 
neutrophil attachment. Cloning data for GMP-140 from an endothelial library predict a soluble 
form of the protein, the transcription message for which is also found in platelets. In this study, 
we report the detection by enzyme-linked immunosorbent assay of soluble GMP-140 in plasma 
centrifuged for 3 h at 100,000 g  (to remove platelet micropartides) and confirm its identity by 
purification from plasma. Plasma concentrations were found to be 0.251  _+ 0.043 I~g/ml (~  • 
SD, n  --  10) in normal male controls and 0.175  _+ 0.063/zg/ml (~  _+  SD, n  =  10) in normal 
female controls. The purified protein had an identical molecular mass (nonreduced) to platdet 
membrane GMP-140 (,,o3 kD lower, reduced) and was immunoblotted by polyclonal anti-GMP- 
140, and the anti-GMP-140 monoclonal antibodies AK4 and AK6. Analytical gel filtration studies 
indicated that the plasma GMP-140 eluted as a monomer whereas detergent-free, platelet membrane 
GMP-140 eluted as a tetramer consistent with plasma GMP-140 lacking a transmembrane domain. 
Purified plasma GMP-140 bound to the same neutrophil receptor as the membrane-bound form, 
and when immobilized on plastic, bound neutrophils equivalently to immobilized platelet membrane 
GMP-140. Since it has been shown that fluid-phase GMP-140 is anffinfl~rnmatory and downregulates 
CD18-dependent neutrophil adhesion and respiratory burst,  its presence in plasma may be of 
major importance in preventing the inadvertent activation of neutrophils in the circulation. 
G 
MP-140 (P-selectin) is a member of a family of cell adhe- 
sion receptors termed selectins,  which mediate one or 
more aspects  of leukocyte adhesion (1,  2).  Selectins share 
a common structural theme: an NH2-terminal calcium-de- 
pendent lectin domain, an epidermal growth factor motif, 
a variable number of repeats of a sequence found in comple- 
ment regulatory proteins, a transmembrane domain, and a 
short cytoplasmic tail (3). For GMP-140, each of these do- 
mains is encoded by separate exons (4). Cloning data from 
an endothelial cell library predicts the existence of three sep- 
arate forms of GMP-140, two of which differ in the number 
of complement regulatory protein repeats, while a third form 
lacks a transmembrane domain, and hence predicts a soluble 
form of GMP-140 (3).  In support of this, human platelets 
have been found to contain approximately equal amounts of 
mRNA encoding for GMP-140 with and without the trans- 
membrane domain (4). 
Surface-expressed membrane GMP-140 mediates the binding 
of activated platelets to myeloid cells and the transient adhe- 
sion of neutrophils to thrombin-stimulated endothelial cells 
(2,  5).  In contrast, we have found that GMP-140 can also 
serve an antiinflammatory function in that exposure of TNF- 
o~-activated  neutrophils to fluid-phase platelet membrane GMP- 
140 inhibits their CD18-dependent adhesion to resting en- 
dothelium (6) and superoxide production (7). In the present 
study, we demonstrate that soluble GMP-140 circulates in 
normal plasma in a soluble and potentially functional form 
and is secreted from activated platelets. 
Materials and Methods 
Monoclonal and Polyclonal Anti-GMP-140 Antibodies,  The mu- 
rine mAbs AK4 and AK6, at~nity-purified rabbit polyclonal anti- 
GMP-140 antibody, and preparation of nonimmune rabbit IgG have 
been previously described (8, 9). LeoA1 is a routine mAb directed 
against the 65-kD PTA1 antigen (10). 
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platelets were isolated from anticoagulated venous blood either in 
the  presence or absence of PGEt (3 /~M, final concentration). 
Platelets (109/ml) isolated in  the  absence of PGE1 were subse- 
quently activated by the addition of o~ thrombin (1 U/ml, final 
concentration).  Resting  (PGE  0  and  activated ((x  thrombin) 
platelets were pelleted by centrifugation at 1,000 g. The platelet 
supernatants were recentrifuged at  1,500 g  to remove residual 
platelets, and divided in two, with one sample being further cen- 
trifuged at 100,000 g for 3 h. Samples were analyzed under non- 
reducing conditions on a 5-20% gradient SDS-polyacrylamide  gel, 
transferred to nitrocellulose,  and immunoblotted for GMP-140 using 
affinity-purified  rabbit anti-GMP-140 antibody (1/~g/ml) or rabbit 
nonimmune IgG (1 /~g/ml) as control. 
Detection and Quantitation of Plasma GMP-140 by ELISA.  Ve- 
nous blood was collected from normal laboratory volunteers who 
had been medication free for 10 d before study. Blood (nine parts) 
was collected  using a 19-gange  Terumo-winged  infusion set directly 
into 3.2% trisodium  citrate (one part) as anticoagulant  and processed 
immediately.  Alternatively,  in some experiments in order to mimic 
normal hospital collection procedures, venous blood collected  with 
a 21-gauge  needle  was added to a 5-ml buffered sodium citrate vacu- 
tainer (Becton  Dickinson & Co., Mountain View, CA) and allowed 
to sit 2 h before processing. Platelet-poor plasma was prepared by 
centrifugation at 1,500 g for 20 min, then microfuged at 10,000 
g for 5 min, and finally  ultracentrifuged at 100,000 g for 3 h. GMP- 
140-depleted plasma was prepared by batch absorption overnight 
of ultracentrifuged plasma with AK4-Affigel-10  followed by cen- 
trifugation at 1,500 g for 20 min. Surface-expressed GMP-140 on 
platelets was quantitated as previously described (8). 
Plasma GMP-140 levels were quantitated using a sandwich  ELISA 
that employed immobilized affinity-purified  rabbit anti-GMP-140 
antibody and detection with the murine anti-GMP-140 mAb AK6. 
Briefly, 200/~1 of affinity-purified  rabbit anti-GMP-140 antibody 
(0.4/~g/ml) in 0.1 M sodium bicarbonate  buffer, pH 8.3, was added 
to each well of an EIA microtiter plate (Linbro/Titertek, McLean, 
VA) and incubated  overnight  at 4~  After three washes  with ELISA 
buffer (0.12 M NaC1, 0.02 M imidazole, 0.005 M citric acid, 0.1% 
[wt/vol] BSA, pH 7.3), each well was blocked with 5% (wt/vol) 
BSA in ELISA  buffer for 1 h at room temperature. After washing 
three times, 20 #1 of each plasma was added to each of three wells 
containing 180 txl of ELISA buffer. For each experiment, a stan- 
dard curve was generated using purified platelet membrane GMP- 
140 (0-1.6/~g/ml,  final concentrations). For the standard curve, 
20/~1 of serially diluted platelet membrane GMP-140 was added 
in triplicate to 160/~1 of ELISA buffer and 20 #1 of GMP-140- 
depleted plasma. After 1 h, the plates were washed four times, and 
200/~1 of AK6 IgG in ELISA buffer (2.5/~g/ml,  final) was then 
added. After 1 h, the plate was rewashed five times and 200/zl 
of a i in 1,000 dilution of horseradish  peroxidase-conjugated  rabbit 
anti- mouse IgG was added for 1 h. The plate was washed five 
times and color developed using 200/~l/well  of 0.42 M 3,3',5, 
5'-tetramethylbenzidine dihydrochloride in 0.1 M acetate buffer, 
pH 6, containing 1.3 mM hydrogen peroxide. The reaction was 
stopped after 10 min by the addition of 50/~1 of 2 M sulphuric 
acid. Absorbance was then read on an automated reader (EL312; 
Biokinetics, Winooski,  VT) at 450 vs. 490 nm. 
Purification of  Plasma GMP.140.  Fresh  platelet-poor plasma ob- 
tained on the day of collection from the Red Cross Blood Bank 
(Parramatta, Sydney)  was centrifuged at 10,000 g for 1.5 h in order 
to remove residual platelets. Buffers used for the purification of 
plasma GMP-140 included 0.1% (wt/vol) Triton X-100, due to the 
marked propensity of plasma GMP-140 to irreversibly absorb to 
surfaces during its isolation. The plasma was loaded onto an AK6- 
Affigel-10 column that had been equilibrated with 0.01 M Tris, 
0.15 M NaC1, 0.1% (wt/vol) Triton X-100, and 0.02% (wt/vol) 
sodium azide, pH 7.4 (buffer A). After exhaustive washing with 
buffer A and buffer A made 1 M in NaC1 and 1 mM in EDTA, 
the column was eluted with 0.1 M glycine, 0.1% (wt/vol) Triton 
X-100, pH 2.4, and immediately  neutralized  by the addition of  one- 
fifth volume of I M Tris, pH 8.0. GMP-140-rich fractions as evalu- 
ated by SDS-PAGE  were pooled  and dialyzed  overnight  against  buffer 
A. BSA (10 mg/ml) was then added to help prevent nonspecific 
absorption of contaminating proteins in the next immunoaffinity 
step. The crude GMP-140 was then loaded onto sequential LeoA1- 
Affigel-10 and AK4-Affigel-10  columns. After thorough washing 
of the AK4 column, bound GMP-140 was eluted, neutralized, and 
then dialyzed against buffer A as described above. GMP-140-rich 
fractions were then loaded onto a column of heparin-Sepharose Cb 
6B. Purified GMP-140 was eluted using a 50-ml linear 0.15-1.0 M 
NaC1 gradient in buffer A. Platelet  membrane  GMP-140 was purified 
from human platelets as previously described in detail (8). Triton- 
X-100 was removed from purified platelet membrane and plasma 
GMP-140 using Extractigel-D resin as previously described (9). 
Platelet membrane and plasma GMP-140 were 12SI-labeled as de- 
scribed (9). 
Interaction of  Plasraa GMP-140 with Neutrophils.  Neutrophil iso- 
lation, binding of 12SI-labeled GMP-140 to neutrophils, and adhe- 
sion of neutrophils to GMP-140-coated plastic were all performed 
as previously described in detail (6-8). 
Analytical Methods.  NH2-terminal  peptide sequence analysis, 
analytical  gel filtration, SDS-PAGE, gel staining, and Western blot 
analysis  were performed as previously  described  in detail (9, 11, 12). 
Results 
Secretion of GMP-140 from  Platelets.  Since  cDNA  and 
platdet mRNA analysis both predict a soluble form of GMP- 
140 with a ddeted transmembrane domain (3,  4), we ini- 
tially examined whether GMP-140 was secreted from phtdets 
on activation. GMP-140 could be detected by Western blot 
analysis in the supernatant of thrombin-stimulated platdets 
but not control platelets (Fig.  1 B, lane 2 vs. Fig. 1 A, lane 
2), even after the platelet supernatant had been centrifuged 
at 100,000 g for 3 h (Fig.  1 B, lane 3). The majority of the 
platdet GMP-140, however, remained platdet-associated  after 
thrombin stimulation (Fig.  1 B, lane I  vs.  Fig.  1 A,  lane 
I). Since platdet microparticles  that contain GMP-140 would 
sediment at  100,000 g  (13), this experiment suggests that 
GMP-140  can exist in soluble form. 
Detection of GMP-140 in Plasma.  A  sensitive  ELISA for 
the measurement of GMP-140 levels  in ultracentrifuged  plasma 
was developed. Addition of  known amounts of  purified phtelet 
membrane GMP-140 to either GMP-140-depleted plasma or 
normal plasma indicated that the determined level of GMP- 
140 in plasma was strictly additive at 0-1.0 t~g/ml. Plasma 
from 10 normal male and 10 normal female donors (age range, 
20-40 yr) gave GMP-140 levels of 0.251  __  0.043 and 0.175 
_+  0.063 t~g/ml (~  --  SD), respectively  (p <  0.01, unpaired 
student's t test). Western blot analysis of serially diluted plasma 
and known amounts of platelet membrane GMP-140  were 
also consistent with a plasma level of GMIX140 of'~0.2/~g/ml 
(data not shown). Under our standard conditions for venous 
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140 from platdets. Control (,4) 
and thrombin-activated  platelets 
(B) were  separated  on a 5-20% ex- 
ponential  SDS-polyacrylamide  gel, 
transferred to nitrocdhlose, and 
immunoblotted with  a/finity- 
purified  rabbit anti-GMP-140  an- 
tibody.  Lane  1, phtdet pellet;  lane 
2,  platelet supernatant; lane 3, 
platelet supernatant centrifuged 
at 100,000 g for 3 h. Molecular 
weight  markers  in decreasing  order 
are myosin (200,000), B-galac- 
tosidase  (130,000), phosphorylase 
B (94,000), BSA (68,000), and 
OVA (43,000). 
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Figure 3.  Neutrophil adherence  to GMP-140-coated  plastic. Neutro- 
phil adherence  to increasing  concentrations  of  immobilized  platelet  mem- 
brane GMP-140 (O) and plasma GMP-140 (@). 
blood sampling, the platdets in platelet-rich plasma had <100 
copies of surface-expressed GMP-140 compared with -10,000 
copies on the surface of fully activated platelets (1), indicating 
that the plasma GMP-140 did not arise due to platelet activa- 
tion during sample collection. In addition, the plasma GMP- 
140 level was insensitive to different collection procedures 
(Materials and Methods), indicating that the assay could be 
applied to routinely collected, hospital-citrated  plasma samples. 
Finally, the plasma GMP-140 level in plasma centrifuged at 
10,000 g  for 5 min vs. plasma centrifuged at 100,000  g  for 
3  h  was not  significantly different, indicating that plasma 
GMP-140 could not be accounted for as microparticle con- 
tamination. In this regard, it can be calculated from the data 
of George et al. (13) that microparticle-associated GMP-140 
Figure 2.  Analysis  of  purified  GMP-140  by SDS-PAGE.  Purified  platdet 
membrane  GMP-140 (10/tg, lane 1) and plasma GMP-140 (5/~g, lane  2) 
were  analyzed  on a 5-15% exponentialSDS-polyacrylamide  gel under  non- 
reducing  and reducing  conditions  and stained  for protein  with coomassie 
brilliant blue. Molecular  weight markers  in decreasing  order are myosin 
(200,000), 3-galactosidase (130,000), phosphorylase B (94,000), BSA 
(68,000) and OVA (43,000). Bottom arrow indicates the position of the 
dye front. 
in normal plasma would account for <0.05 ng/ml of plasma 
GMP-140. 
Purification of Plasma GMP-140.  GMP-140 was purified 
to  homogeneity from pooled  normal  human plasma  (see 
Materials and Methods) with an overall yield of "~100/~g 
from 6 liters of starting plasma.  Relative to platelet mem- 
brane GMP-140, the purified protein had similar binding char- 
acteristics to heparin, a similar molecular mass on SDS-PAGE 
under nonreducing and reducing conditions (Fig. 2), cross- 
reacted with monoclonal and polyclonal anti-GMP-140 anti- 
bodies (data not shown), and had an identical NH2-terminal 
peptide sequence, WTYHYSTKAYSWXFSR  (3).  Plasma 
GMP-140, however, differed from platelet membrane GMP- 
140 in that its reduced molecular mass on SDS-polyacrylamide 
gels was "~3 kD lower (Fig.  2), and in that on analytical gel 
filtration under detergent-free conditions, it did not elute as 
tetramers (9) but remained monomeric. Both these results 
are consistent with the plasma form of GMP-140 lacking a 
transmembrane domain. Given that platelets contain mRNA 
encoding soluble GMP-140 (4) and that soluble GMP-140 is 
secreted from activated platelets (this study), it is probable 
that  plasma  GMP-140  represents  the alternatively spliced, 
soluble form of GMP-140 lacking the transmembrane sequence 
encoded by exon 14 (4).  It remains possible,  however, that 
plasma GMP-140 is proteolytically derived from the mem- 
brane-bound form of GMP-140. 
Plasma GMP-140 Is Functional.  Since we have previously 
established that fluid-phase GMP-140 regulates various aspects 
of neutrophil function, it was important to establish whether 
plasma GMP-140 retained the capacity to interact with neu- 
trophils. Plasma GMP-140 bound specifically to neutrophils. 
As for binding of platelet membrane GMP-140  to neutro- 
phils (9, 14), this binding was divalent-cation dependent, as 
it was inhibited by excess EDTA. In addition, binding was 
completely inhibited by affinity-purified  rabbit anti-GMP-140 
Fab  fragments,  inhibited  by  *50%  by  the  anti-GMP- 
140 mAb AK4, but not by AK6 (9). Excess plasma GMP-140 
completely inhibited the binding of radioiodinated platelet 
membrane GMP-140 to neutrophils (and vice versa) suggesting, 
as expected, that both the platelet membrane and plasma forms 
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Finally, neutrophils bound equally well to platelet membrane 
and plasma GMP-140  immobilized on plastic  (Fig. 3). 
Discussion 
Current  evidence  suggests  that  GMP-140  plays  a  fun- 
damental role in both limiting and mediating the inflamma- 
tory responses of neutrophils (2, 6, 7). In the present study, 
we demonstrate that GMpo140 circulates  in a soluble and 
potentially functional form in plasma and is secreted in soluble 
form from activated platelets.  In normals, the plasma con- 
centration of GMP-140 was found to be •0.15-0.30  #g/ml. 
Based on the measured binding characteristics  of fluid-phase 
platelet membrane GMP-140  to neutrophils (9), this would 
correspond to 20-40%  saturation of neutrophil GMP-140 
receptors, potentially allowing both an antiinflammatory  ac- 
tion (6, 7) as well as the focal adhesion of neutrophils to GMP- 
140 expressed  on activated endothelium (2). 
GMP-140  has  only been localized  to the cr  granules of 
platelets (and megakaryocytes) and the Weibel-Palade bodies 
of endothelium (1), and is surface expressed on both cell types 
on cellular activation. Since mRNA encoding the soluble form 
exists in both endothelium (3) and platelets (4), plasma GMP- 
140 must derive from either one or both of these sources. 
One would therefore predict that the plasma level of GMP- 
140 could provide a useful marker of either platelet activa- 
tion and/or vascular endothelial perturbation in thrombotic 
and inflammatory diseases. This topic is under current inves- 
tigation. 
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